Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$5.26 - $8.28 $147,937 - $232,874
28,125 New
28,125 $231,000
Q4 2023

Feb 13, 2024

BUY
$5.44 - $9.5 $107,048 - $186,941
19,678 New
19,678 $176,000
Q2 2023

Aug 11, 2023

BUY
$15.3 - $22.61 $279,546 - $413,107
18,271 New
18,271 $280,000

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.12B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.